73335-64-5 Usage
General Description
N-Methyl-(5-bromopyrid-3-yl)methylamine is a chemical compound, often referred to as an intermediate, used in organic synthesis to produce other chemicals. Its systematic name is [5-bromo-3-pyridinyl(methyl)amino], possessing the molecular formula C6H8BrN. Being a bromine derivative, it's characterised by a bromo functional group and a pyridine ring, imparting it with an ability to participate in various reactions. Typically, this chemical is used in laboratories and industrial settings, and must be handled with care due to its reactivity. Its data details like optimal storage conditions, potential hazards, physical properties, and biological activity, are usually provided by the manufacturers for safe and effective use.
Check Digit Verification of cas no
The CAS Registry Mumber 73335-64-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,3,3,3 and 5 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 73335-64:
(7*7)+(6*3)+(5*3)+(4*3)+(3*5)+(2*6)+(1*4)=125
125 % 10 = 5
So 73335-64-5 is a valid CAS Registry Number.
InChI:InChI=1/C7H9BrN2/c1-9-3-6-2-7(8)5-10-4-6/h2,4-5,9H,3H2,1H3
73335-64-5Relevant articles and documents
1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS
-
Page/Page column 34-36, (2020/01/10)
The present invention relates to the 1 H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3β) inhibitors and to their use in the treatment of GSK-3β-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) osteoporosis, (viii) cardiac hypertrophy, (ix) epilepsies and (x) neuropathic pain.
NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS
-
Page/Page column 68; 73, (2015/04/22)
The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.
